FLT3 tyrosine-kinase inhibitor
Quizartinib (Specialist drug)
Brand names: Vanflyta
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD
Clinical pearls
- FLT3-ITD AML — induction/consolidation/maintenance with chemotherapy
- Specialist haem-onc; ECG monitoring
Contraindications
- QT prolongation
- Hypersensitivity
Side effects
- QT prolongation (black box — Torsades, sudden death)
- Cytopenias
- Infections
- Hepatotoxicity
- Pancreatitis
Interactions
- Strong CYP3A4 modulators
- QT-prolonging drugs
Monitoring
- ECG
- FBC
- LFTs
- Lipase
- Electrolytes
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/quizartinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
- Anticoagulation Reversal · BSH 2016 / ESC